Abralipedema

Abralipedema is a biotechnology company focused on developing therapeutic solutions for lipedema, a chronic medical condition characterized by a symmetric buildup of adipose tissue in the limbs. The company aims to address the underlying biological mechanisms of the disease, which currently lacks FDA-approved pharmacological treatments. Abralipedema's research efforts are directed toward identifying novel targets and small molecule candidates to reduce inflammation and fibrotic changes associated with the condition. By advancing its pre-clinical pipeline, the company seeks to improve the quality of life and clinical outcomes for patients suffering from this often-misdiagnosed lymphatic and metabolic disorder.